![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112
|
|
|
Reported by Jules Levin
8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, Vancouver, Canada BC
Samir K. Gupta1, Anton Pozniak2, Jose Arribas3, Frank A. Post4, Mark Bloch5, Joseph Gathe6, Paul Benson7, Joseph Custodio8, Michael Abram8, Xuelian Wei8, Andrew Cheng8, Scott McCallister8, Marshall W Fordyce8
1Indiana University School of Medicine, Indianapolis, IN, USA; 2Chelsea and Westminster Hospital NHS Foundation Trust, London, UK; 3Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; 4King's College Hospital NHS Foundation Trust, London, UK; 5Holdsworth House Medical Practice, Darlinghurst, NSW, AUS 6Therapeutic Concepts, Houston, TX, USA; 7Be Well Medical Center, Berkley, MI, USA; 8Gilead Sciences, Foster City, CA, USA
![IAS1.gif](../images/072215/072215-7/IAS1.gif)
![IAS2.gif](../images/072215/072215-7/IAS2.gif)
![IAS3.gif](../images/072215/072215-7/IAS3.gif)
![IAS4.gif](../images/072215/072215-7/IAS4.gif)
![IAS5.gif](../images/072215/072215-7/IAS5.gif)
![IAS6.gif](../images/072215/072215-7/IAS6.gif)
![IAS7.gif](../images/072215/072215-7/IAS7.gif)
![IAS8.gif](../images/072215/072215-7/IAS8.gif)
![IAS9.gif](../images/072215/072215-7/IAS9.gif)
![IAS10.gif](../images/072215/072215-7/IAS10.gif)
![IAS11.gif](../images/072215/072215-7/IAS11.gif)
![IAS12.gif](../images/072215/072215-7/IAS12.gif)
![IAS13.gif](../images/072215/072215-7/IAS13.gif)
![IAS14.gif](../images/072215/072215-7/IAS14.gif)
![IAS15.gif](../images/072215/072215-7/IAS15.gif)
![IAS16.gif](../images/072215/072215-7/IAS16.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|